L'Università di Modena e Reggio Emilia è un'università statale italiana, fra le più antiche d'Europa, le cui origini come Studium a Modena risalgono al 1175 e, a Reggio, al 1188. Dopo diversi secoli, fu rifondata nel 1682.

During the past decade, Università di Modena e Reggio Emilia conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 4 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Università di Modena e Reggio Emilia" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials sponsored, "Fondazione Italiana Linfomi ONLUS" with 1 trials sponsored, "Northwestern University" with 1 trials sponsored and "Policlinico Casilino ASL RMB" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Università di Modena e Reggio Emilia" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "CIHR Canadian HIV Trials Network" with 1 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator, "San Raffaele University Hospital, Italy" with 1 trials as a collaborator and "University College, London" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Università di Modena e Reggio Emilia" are "HIV" (2 trials), "HIV Infections" (2 trials), "Idiopathic Pulmonary Fibrosis" (2 trials), "ADPKD" (1 trials) and "AIDS" (1 trials). Many other conditions were trialed in "Università di Modena e Reggio Emilia" in a lesser frequency.

Most popular intervention types in "Università di Modena e Reggio Emilia" are "Drug" (8 trials), "Device" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Nintedanib" (2 trials), "Atazanavir" (1 trials), "BIBF 1120" (1 trials), "Bardoxolone methyl oral capsule" (1 trials) and "Deep Ensemble for the Recognition of Malignancy (DERM)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Università di Modena e Reggio Emilia" are 12 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Università di Modena e Reggio Emilia". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 8 completed trials in Università di Modena e Reggio Emilia, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Università di Modena e Reggio Emilia, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".